SkyShowtime Announces Official Launch Date and Content Line-Up
14.9.2022 17:56:00 EEST | Business Wire | Press release
New streaming service SkyShowtime today announced that it will officially launch on 20 September 2022, bringing its premium offering of exclusive and iconic entertainment to millions of homes across Europe for the first time.
A joint venture of Comcast (NASDAQ: CMCSA) —parent company of NBCUniversal and Sky— and Paramount Global (NASDAQ: PARA, PARAA), SkyShowtime will launch in Denmark, Finland, Norway and Sweden on 20 September, before expanding into the Netherlands later this year in Q4. SkyShowtime will continue its roll out across Spain, Portugal, Andorra, and Central & Eastern Europe (CEE) over the coming months and through Q1 2023. CEE markets include Albania, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Hungary, Kosovo, Montenegro, North Macedonia, Poland, Romania, Serbia, Slovakia and Slovenia. Specific launch dates and pricing in these markets will be announced in the coming months.
SkyShowtime brings together the best entertainment from the world’s greatest studios and storytellers. Featuring thousands of hours of quality entertainment for the whole family, the service will be home to a wide selection of the world’s most highly anticipated series and movies.
It will feature the exclusive television premieres of first-run theatrical films from Paramount Pictures and Universal Pictures, Hollywood’s two oldest studios and which together account for nearly 50% of Hollywood box office.
SkyShowtime will be the home to a selection of new blockbuster films following their theatrical and home entertainment release, including Top Gun: Maverick, Jurassic World Dominion, Minions: The Rise of Gru, The Northman, Sing 2, Sonic the Hedgehog 2, The Lost City, Downton Abbey: A New Era, Nope, Belfast, Ambulance and The Bad Guys.
In addition, SkyShowtime features new premium scripted series, kids and family content and a selection of iconic library titles and box sets from Universal Pictures, Paramount Pictures, Nickelodeon, DreamWorks Animation, Paramount+, SHOWTIME®, Sky Studios and Peacock - all streaming in one place. SkyShowtime will also feature local original programming, documentaries and specials from its markets.
In the Nordics, as part of the partnership with Paramount, SkyShowtime will replace Paramount+, allowing existing and future customers to watch current Paramount+ favourites such as Halo, Yellowstone, The Offer and Star Trek: Strange New Worlds, as well as SHOWTIME® originals Yellowjackets, Dexter: New Blood, Super Pumped: The Battle for Uber, and The First Lady. And for the first time, subscribers will gain access to even more new and exclusive premium series and movies spanning the best of Universal Pictures, Sky Originals and NBCUniversal.
From launch, customers can watch series premieres of highly anticipated SHOWTIME® drama American Gigolo, Sky Originals The Rising, The Fear Index, and The Midwich Cuckoos, as well as Law & Order Season 21 from Peacock. Over the coming months, additional series premieres will include Yellowstone Season 5, Pitch Perfect: Bumper in Berlin, Vampire Academy and SHOWTIME® series Yellowjackets Season 2 and Let The Right One In.
SkyShowtime CEO Monty Sarhan said: “It’s time… for SkyShowtime, — the next great streaming service for Europe. Just months after receiving full regulatory approval, SkyShowtime will officially launch on 20 September 2022. We’re excited for our customers to have exclusive access to the latest series and movie premieres from our iconic and world-renowned studios. We look forward to sharing further details about launch dates for our other markets and bringing SkyShowtime to even more people across Europe.”
SkyShowtime Regional General Manager for Northern Europe Henriette Skov commented: “We’re thrilled to launch SkyShowtime across the Nordics and look forward to offering our customers the very best selection of global series and movies all in one place.”
The service will be available direct-to-consumer via the SkyShowtime app across Apple iOS, tvOS, Android devices, and through the website: www.skyshowtime.com. SkyShowtime’s monthly price will be €6,99 in Finland, SEK 79 in Sweden, NOK 79 in Norway, and DKK 69 in Denmark.
SkyShowtime will also be available through the following distribution partners across its Nordic markets: Allente, RiksTV, Ruutu, Sappa, Strim, Telenor, Tele2, Telia, Telmore and YouSee from Nuuday Group, and TV 2 Play.
Powered by the Peacock platform, SkyShowtime was created specifically for Europe and is dedicated to these markets. With regional offices across its territories, SkyShowtime’s customer-centric focus and local market presence informs its approach to partnerships, content, and marketing. Once launched across more than 20 countries, SkyShowtime’s apps and content will be available in 18 different languages.
The content line up detailed in this press release is Nordic-specific and may vary per market.
For the trailer, please access here: https://youtu.be/ujzpT7FTeeY
For more details, please visit:
Website: www.skyshowtime.com
Newsroom: corporate.skyshowtime.com
LinkedIn: www.linkedin.com/company/skyshowtime
For further information, please email skyshowtimeenquiries@mcsaatchi.com
About SkyShowtime
SkyShowtime is a new streaming service that will launch in the Nordics on 20th September, this year.
A joint venture of Comcast Corporation (NASDAQ: CMCSA) and Paramount Global (NASDAQ: PARA, PARAA), SkyShowtime brings together the combined resources of both companies, direct-to-consumer experience, and the very best entertainment, movies, and original series from the iconic brands of Universal Pictures, DreamWorks, Sky Studios, Peacock, Paramount +, SHOWTIME®, Paramount Pictures and Nickelodeon.
SkyShowtime will be available in more than 20 European markets encompassing 90 million homes. It will be offered in Albania, Andorra, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Denmark, Finland, Hungary, Kosovo, Montenegro, Netherlands, North Macedonia, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Slovenia, Spain, and Sweden.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220905005022/en/
Contact information
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Wyss Geneva Steps Into Its Next Chapter11.6.2026 14:33:00 EEST | Press release
The Wyss Center for Bio and Neuroengineering in Geneva is pleased to announce the appointment of Dr. Tracy Laabs as Director, effective July 1st 2026. Dr. Laabs succeeds Prof. Dr. Erwin Böttinger, who leaves behind a fundamentally transformed organization: one that no longer just pursues breakthrough science but systematically turns it into ventures that reach patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611328520/en/ Dr. Tracy Laabs, incoming Director, Wyss Center Geneva Since joining the Wyss Center as Director in April 2023, Prof. Böttinger brought a bold vision: to evolve the Center from a portfolio of promising projects into a disciplined engine for venture creation. Under his leadership, the Center spun off six companies in two years (including ABILITY Neurotech SA and Clee Medical SA in 2025) while simultaneously building a robust pipeline of next-generation programs in AI-guided neuromodulation and min
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit11.6.2026 14:24:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its role as the foundational BTK inhibitor. BRUKINSA is the only BTK inhibitor to demonstrate superior efficacy vs. ibrutinib in a Phase 3 trial.1 These data, one of the largest datasets of older patients with treatment-naive CLL, will be presented at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: "While the median age of diagnosis for CLL is 70 and the average age of treatment initiation is 75, many pivotal trials still underrepresent the patients that physicians most often see in practice. These data show that the durable benefit of
Clearlake Expands Liquid Credit Platform With Acquisition of LCM Asset Management’s CLO Contracts11.6.2026 14:00:00 EEST | Press release
Clearlake Capital Group, L.P. (“Clearlake” or the “Firm”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced that its credit platform, Clearlake Credit, will assume management of CLOs managed by LCM Asset Management, LLC. The transaction adds 31 CLOs representing more than $5 billion of assets under management and increases assets managed by Clearlake Credit to approximately $39 billion across liquid credit, private credit, and other customized credit solutions. The acquisition further broadens the Firm’s capabilities, deepens its relationships with institutional investors, and reinforces its client-centric approach and commitment to seeking attractive risk-adjusted returns across market cycles. Milbank LLP and Dechert LLP represented Clearlake Credit in the transaction. GreensLedge Capital Markets advised the seller. About Clearlake Clearlake Capital is a leading global alternative a
Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations11.6.2026 14:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). In the LATITUDE Atlas (TAK-279-PsO-3004) head-to-head study, zasocitinib demonstrated statistical superiority over deucravacitinib for the primary endpoint, Psoriasis Area and Severity Index (PASI) 100 response rate at week 16. The study also demonstrated statistical superiority over deucravacitinib for all key secondary endpoints, including PASI 90 response and Static Physician's Global Assessment (sPGA) 0 at week 16. Zasocitinib was generally well tolerated with a consistent safety and tolerability profile and no new safety signals identified. Perspectives on head-to-head zasocitinib study “In this head-to-head study, zasocitinib clearly demonstrated
L&T Technology Services, Databricks Partner to Deliver Industrial AI at Scale for Asset-Intensive Industries11.6.2026 13:30:00 EEST | Press release
L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced a strategic go-to-market partnership with Databricks, the leading Data and AI company, to co-develop and deliver Industrial AI solutions that advance Engineering Intelligence (EI) for asset-intensive enterprises. Anchored in LTTS' Sustainability segment, spanning Process Engineering, Discrete Manufacturing and Industrial Products, the partnership will support Energy, Petrochemicals and Industrials clients globally. As industrial organizations seek to unlock greater value from decades of operational and engineering data, the alliance will combine LTTS’ deep domain capabilities with the Databricks platform to transform complex plant data into Engineering Intelligence - enabling improved asset reliability, operational efficiency and sustainability performance. The partnership brings together LTTS’ expertise in forward looking technologies and extensive experience ac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom